Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468303 | 0.83 | AAK1 (0.47) | AAK1TRPA1GABRB1GABRB2LCK | |
| SCHEMBL16532762 | 0.82 | AAK1 (0.50) | AAK1EGLN1LCK | |
| SCHEMBL20465386 | 0.79 | AAK1 (0.46) | AAK1TRPA1GABRB1GABRB2PRCP | |
| SCHEMBL20054545 | 0.79 | AAK1 (0.64) | AAK1LCKSCN10A | |
| SCHEMBL15116826 | 0.79 | AAK1 (0.64) | AAK1LCKSCN10A | |
| SCHEMBL13498185 | 0.78 | AAK1 (0.48) | AAK1TRPA1PRCP | |
| SCHEMBL2505194 | 0.78 | AAK1 (0.48) | AAK1TRPA1PRCP | |
| SCHEMBL2505196 | 0.78 | AAK1 (0.48) | AAK1TRPA1PRCP | |
| SCHEMBL15116746 | 0.78 | AAK1 (0.50) | AAK1LCKBCHEPTPN1SCN10A | |
| SCHEMBL20054435 | 0.78 | AAK1 (0.50) | AAK1LCKBCHEPTPN1SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885TRPA1 4722/4885GABRB1 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.